Trainees in medical oncology, radiation oncology and surgical oncology are invited to attend the Breast Cancer Trials inaugural Trainee Day, at the 43rd Annual Scientific Meeting.
This is a free multi-disciplinary session, with both presentations and MDT panel discussions from leading Australian and International breast cancer experts.
The Trainee Day will be held on Saturday 30 July from 9am – 3pm, at The Langham Melbourne.
The day will focus on the management of early breast cancer with updates on the latest in evidenced based research. Topics to be covered include:
- Management of the axilla
- Radiotherapy post mastectomy – who receives it and how to treat it
- How, what and when to use gene expression profiling tests such as Oncotype DX
- Immunotherapy in triple negative, early-stage breast cancer – balancing the benefits and risks
- Controversies in the management of DCIS
- Fertility preservation and pregnancy after breast cancer
- Genetics update and risk management in the clinic
This is a fantastic networking and professional development opportunity with leading BCT researchers and other trainees.
For more information please contact the ASM Secretariat at asm@bctrials.org.au
To register for this free event, click here.
Saturday 30 July 2022 Trainee & Early Career Day Program
|
Trainee Session: 9:00 am – 3:30 pm Session Chairs: |
||
|
9:00 am |
Session Chair – Dr Sofia Mason and Dr Katherine Francis |
Introduction to training session |
|
9:10 am (20p:10q) |
Professor Laura Esserman |
Management of the Axilla |
|
9:40am (20p:10q) |
Dr Miriam Boxer |
Adjuvant Radiotherapy – Opportunities for de-escalation |
|
10.10 am (20p:10q) |
Dr Belinda Kiely |
Genomic Profiling – How, When and What? |
|
10:40 am |
Break |
|
|
11:00 am (20p:10q) |
Dr Reuben Broom |
What’s new in neoadjuvant therapy for Triple Negative Breast Cancer |
|
11:30 am (20p:10q) |
Dr Holly Keane |
Controversies in DCIS |
|
12:00 pm (20p:10q) |
Professor Ann Partridge |
Fertility and pregnancy after breast cancer |
|
12.30 pm (20p:10q) |
Dr Milita Zaheed |
Genetics Update/ Risk Management in clinic |
|
1:00 pm |
Lunch |
|
|
1:45 pm |
Session Chair – Dr Sofia Mason and Dr Katherine Francis |
Welcome back/ Open to MDT and introduce panel |
|
1:50 pm |
Dr Nick Zdenkowski |
Trainee Opportunities with Breast Cancer Trials |
|
2:00 pm |
MDT Panel discussion with panel Panel: Ms Leslie Gilham, Dr Nick Zdenkowski, Professor Ann Partridge, Milita Zaheed, A/Prof Lesley Stafford, Dr Reuben Broom, Dr Miriam Boxer.
Chaired by: Dr Sofia Mason and Dr Katherine Francis |
MDT Panel Case Base discussion |
|
3:30 pm |
Canapés and Drinks |
|
Trainee & Early Career Day Speakers
Leslie Gilham
Chair of the Consumer Advisory Panel (CAP) of Breast Cancer Trials, participant in the TEXT Clinical Trial, and Clinical Trials Advocate
Leslie Gilham
Chair of the Consumer Advisory Panel (CAP) of Breast Cancer Trials, participant in the TEXT Clinical Trial, and Clinical Trials Advocate
Leslie has a personal and family history of breast cancer. Diagnosed with breast cancer in 2009 she participated in the TEXT clinical trial as part of her treatment regime. Post diagnosis Leslie has become a strong advocate for clinical trials and subsequently joined the Consumer Advisory Panel of Breast Cancer Trials (formerly Australia & New Zealand Breast Cancer Trials Group) in 2011.
In 2018 she became Chair of Breast Cancer Trials Consumer Advisory Panel offering leadership and direction to the Panel as well as continuing to provide a consumers perspective in the clinical trials space. Leslie is currently an Associate Investigator on a number of clinical trials and research projects throughout Australia & New Zealand and is the Co-Ordinator of Breast Cancer Trials IMPACT Advocacy Program. She is a member of the BIG 3-07 / TROG 07.01 DCIS Steering Committee, a member of the Breast International Group Patient Partnership Initiative, the Roche Global Breast Cancer Council and an advisor to the TILs International Working Group.
Leslie is also a Consumer Representative for Breast Cancer Network Australia and is an Independent Advocate collaborating with various Government Agencies and Public and Private Health Institutions.
Miriam Boxer
Member of the RANZCR Professional Practice Committee & previously a Director of Training at Liverpool & Campbelltown Hospitals
Miriam Boxer
Member of the RANZCR Professional Practice Committee & previously a Director of Training at Liverpool & Campbelltown Hospitals
Dr Miriam Boxer obtained her Bachelor of Health Sciences with first class honours, at the University of Adelaide before studying Medicine at Flinders University. She completed her junior doctor training in Wollongong before heading overseas where she worked and travelled before returning home to begin her training in Radiation Oncology. She completed her training at Liverpool and Campbelltown Hospitals, becoming a Fellow of the College of Radiologists in 2010. She stayed in South West Sydney where she worked as a Staff Specialist since 2011 specialising in breast and lung cancer. She was the clinical lead in introducing new and advanced radiation therapy techniques for breast cancer at Liverpool and Campbelltown. She has published research in the areas of peer review and multidisciplinary management of cancer.
Miriam has a passion for education and for 6 years she was the Director of Training at Liverpool and Campbelltown Hospitals where she recruited, mentored and supervised trainees. She is a member of the RANZCR Professional Practice Committee.
Miriam has helped to establish the new Icon Cancer Centre Radiation Oncology Department at Concord hospital which opened early in 2022.
Ann Partridge
Professor of Medicine, Harvard Medical School, & Vice Chair of Medical Oncology, Dana-Faber Cancer Institute
Ann Partridge
Professor of Medicine, Harvard Medical School, & Vice Chair of Medical Oncology, Dana-Faber Cancer Institute
Ann Partridge is a Professor of Medicine at Harvard Medical School, and Vice Chair of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as Director of the Adult Survivorship Program and leads the Program for Young Women with Breast Cancer.
As a medical oncologist and clinical researcher, she has sought to improve the care and outcomes of patients with cancer by conducting research, and by developing innovative clinical programming. Professor Partridge serves in leadership roles nationally and internationally including as co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology and co-chair of the biennial ESMO-ESO sponsored Breast Cancer in Young Women Conference.
She also served as Chair of the Center for Disease Control and Prevention (CDC) Advisory Committee on Breast Cancer in Young Women from 2010-17. She has received prior awards and grants including a Champions of Change award from the White House, an ASCO Improving Cancer Care Grant, the CDC Carol Friedman Award, the American Association for Cancer Research (AACR) Outstanding Investigator Award for Breast Cancer, and the Ellen L. Stovall Award in Cancer Survivorship from ASCO, and the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School.
After graduating from Georgetown University, Professor Partridge received her medical degree from Cornell University Medical College, pursued an internal medicine residency at the Hospital for the University of Pennsylvania, and completed Medical Oncology and Hematology fellowship at Dana-Farber/Partners Cancer Care. She earned a Master of Public Health degree at the Harvard School of Public Health.
Milita Zaheed
Medical Oncologist and staff specialist in Cancer Genetics and Medical Lead for ACT Cancer Genetics Service
Milita Zaheed
Medical Oncologist and staff specialist in Cancer Genetics and Medical Lead for ACT Cancer Genetics Service
Milita Zaheed is a staff specialist in Cancer Genetics at Prince of Wales Hospital and is also the medical lead for ACT Cancer Genetics service. She is a Medical Oncologist and trained in Cancer Genetics through Royal Australian College of Physicians with an NSW Cancer Institute two-year fellowship grant. She is currently doing a PhD in cancer genetics through Garvan Institute investigating opportunities to improve identification of cancer predisposition syndromes in the genomic era of cancer care. She is a past National Medical Oncology trainee representative, current executive committee member of Young Oncologist Group of Australia and COSA Global Oncology Interest Group and Chair of the NSW Familial Cancer Community of practice group.
Laura Esserman
Professor of Surgery and Radiology at the University of California, San Francisco (UCSF) and director of the UCSF Breast Care Clinic
Laura Esserman
Professor of Surgery and Radiology at the University of California, San Francisco (UCSF) and director of the UCSF Breast Care Clinic
Laura Esserman is Professor of Surgery and Radiology at the University of California, San Francisco (UCSF) and director of the UCSF Breast Care Clinic.
Her work in breast cancer spans the spectrum from basic science to public policy issues, and the impact of both on the delivery of clinical care. Professor Esserman is recognized as a thought leader in cancer screening and over-diagnosis, as well as innovative clinical trial design.
She led the creation of the University of California-wide Athena Breast Health Network, a learning system designed to integrate clinical care and research as it follows 150,000 women from screening through treatment and outcomes. The Athena Network launched the PCORI-funded Wisdom Study, which tests a personalized approach to breast cancer screening in 100,000 women.
She is also a leader of the innovative I-SPY TRIAL model, designed to accelerate the identification and approval of effective new agents for women with high risk breast cancers. In 2020 she got FDA approval for an I-SPY Covid trial, designed to rapidly screen and confirm high impact treatments to reduce mortality and time on ventilators.
Nicholas Zdenkowski
Medical Oncologist & Advisor with Breast Cancer Trials, consulting across the Hunter Region in NSW Australia
Nicholas Zdenkowski
Medical Oncologist & Advisor with Breast Cancer Trials, consulting across the Hunter Region in NSW Australia
Nicholas Zdenkowski is a Medical Oncologist and Medical Advisor with Breast Cancer Trials. He sits on the BCT Scientific Advisory Committee and the PALLAS trial Steering Committee. He works on a broad range of breast cancer research, including shared decision-making, clinical trials and patient reported outcomes, particularly around neoadjuvant systemic therapy. His PhD project resulted in the development of a decision aid for patients considering neoadjuvant systemic therapy for breast cancer. He has published widely, from patient reported outcomes, systematic reviews and clinical trial outcomes. He consults at Lake Macquarie Private Hospital and Maitland Private Hospital in the Hunter Region in NSW Australia.